View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Project
12 February 2020

Hitachi Chemical’s Cell and Gene Therapy Manufacturing Facility, New Jersey

Hitachi Chemical Advanced Therapeutics Solutions (HCATS) opened its new manufacturing facility in New Jersey, US, in January 2020, developed to meet the demand for cell and gene therapy manufacturing services.
The new gene and cell therapy manufacturing facility of HCATS is located at 75 Commerce Drive, Allendale, New Jersey. Credit: Hitachi Chemical Advanced Therapeutics Solutions, LLC.
The company held the opening ceremony of its new facility in January 2020. Credit: Hitachi Chemical Advanced Therapeutics Solutions, LLC.
The new facility will be engaged in commercial manufacturing of cell and gene therapy products. Credit: Hitachi Chemical Advanced Therapeutics Solutions, LLC.

Hitachi Chemical Advanced Therapeutics Solutions (HCATS) opened its new manufacturing facility in New Jersey, US, in January 2020, developed to meet the demand for cell and gene therapy manufacturing services.

Free eBook
img

3 Key Tips for a Successful Design Build Project

With supply chain disruptions and inflation creating new challenges for delivery teams, design-build projects are booming. This e-book looks at the 3 essential tips a project delivery team must consider when delivering a successful Design Build project.
by Oracle
Enter your details here to receive your free eBook.

It will manufacture the company’s cell and gene therapy products as well as support clients in commercialising cell and gene therapies. The facility will allow HCATS to expand its manufacturing capacity in New Jersey by more than two times.

The company is expected to hire up to 500 employees to support operations.

Hitachi Chemical’s cell and gene therapy manufacturing facility location

The new cell and gene therapy manufacturing facility is at 75 Commerce Drive, Allendale, New Jersey, covering an area of approximately 55,000ft2.

The company operates another manufacturing facility in Allendale, New Jersey, which serves as the headquarters.

Allendale facility is near significant airports including Newark, John F Kennedy International Airport, and LaGuardia.

Details of Hitachi’s cell and gene therapy manufacturing facility

The facility comprises more than 3,800ft² of classified support areas and 1,200ft² of controlled environment rooms (CERs).

It has six environment rooms, as well as the provision for additional rooms on customer demand.

Infrastructure at the site also includes manufacturing development labs, laboratories dedicated to microbiology and quality control, meeting rooms, executive offices and warehouse.

The facility meets Current Good Manufacturing Practice (cGMP) regulations and covers systems, such as materials, instruments and facility controls, corrective and preventative action (CAPA), validation, internal and external audits and training.

Existing manufacturing facility details

The existing cGMP-compliant manufacturing facility in Allendale covers a total area of 30,000ft², offering manufacturing capabilities to support customers from the product development stage through to clinical manufacturing of cell therapy.

The Allendale facility includes six clean rooms and approximately 1,300ft² of CERs, allowing the company to enhance its cell therapy products manufacturing capability.

As part of the PCT service platform, HCATS also carried out improvements to the existing facility to enable better the process flow.

Marketing commentary on Hitachi Chemical Advanced Therapeutics Solutions

Hitachi Chemical Advanced Therapeutics Solutions operates as a subsidiary of Hitachi Chemical and handles the company’s Regenerative Medicine Business Sector (RMBS) in the North America region. The company offers contract development and manufacturing services in the US through the PCT global platform.

The company has been in the cell therapy industry for more than 20 years. It provides services such as commercial manufacturing, clinical manufacturing and manufacturing development.

“Infrastructure at the site also includes manufacturing development labs, laboratories dedicated to microbiology and quality control, meeting rooms, executive offices and warehouse.”

The company also has a 25,000ft² facility in Mountain View, California, which focuses on manufacturing process development and clinical manufacturing.

In addition to the US facilities, HCATS operates facilities in Munich, Germany, and Yokohama, Japan. The RMBS has a footprint covering more than 200,000ft².

The company offers industry experience in a range of aspects including cell engineering technologies, cell culture and expansion, automation and biological analytical methods.

The expertise will allow customers to advance the commercialisation of products in multiple cell therapies, including T-cells (CAR, TCR, Treg), dendritic cells, natural killer cells, mesenchymal cells, hematopoietic stem cells, as well as autologous and allogeneic applications.

In 2017, Hitachi Chemical acquired the remaining interest in PCT in a $75m transaction, following which, PCT was renamed as Hitachi Chemical Advanced Therapeutics Solutions (HCATS).

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology